Amkay Products Limited has announced a mandatory trading window closure for all designated persons, effective from April 1, 2026. The closure will remain in effect until 48 hours after the company declares its financial results for the financial year ended March 31, 2026.

Regulatory Compliance Details

The trading window closure is implemented in strict adherence to regulatory requirements. The company has cited compliance with SEBI (Prohibition of Insider Trading) Regulation, 2015, read with BSE Circular No. LIST/COMP/01/2019-20 dated April 2, 2019, as the basis for this action.

Company Background

Amkay Products Limited operates as a manufacturer of medical devices and disposables. The company maintains its registered office at Amkay Enclave, 68, Rashmi Park Bungalow, Dhumaal Nagar, Waliv Road, Vasai (East), Palghar - 401208, Maharashtra, India. The company holds ISO 9001:2015 certification and operates under the corporate identity number U51397MH2007PLC175403.

Official Communication

The formal intimation was communicated to BSE Limited on March 25, 2026, through an official letter signed by Kashyap Pravin Mody, Managing Director (DIN: 01717036). The communication was digitally signed and addressed to the Deputy General Manager, Corporate Relationship Department at BSE Limited.

Trading Window Implications

During the closure period, designated persons within the company will be restricted from trading in the company's securities. This measure ensures compliance with insider trading regulations and maintains market integrity during the period leading up to and immediately following the financial results announcement. The trading window will reopen 48 hours after the official declaration of the company's financial results for FY26.

Amkay Products Limited, a manufacturer of medical devices and disposables, has disclosed its financial results for the half-year ended September 30, 2025, revealing a widened net loss and increased expenses despite a rise in revenue.

Financial Performance

The company reported a net loss of Rs 196.80 lakhs for the half-year, compared to a loss of Rs 151.31 lakhs in the corresponding period of the previous year. This represents an increase in losses of approximately 30.1% year-over-year.

Despite the increased loss, Amkay Products saw a 7.8% year-over-year growth in total revenue, which rose to Rs 2,340.45 lakhs from Rs 2,171.45 lakhs in the previous year. However, this revenue growth was offset by a rise in total expenses, which reached Rs 2,071.65 lakhs for the period.

Board Meeting and Audit Review

The Board of Directors of Amkay Products Limited convened on November 12, 2025, to approve the unaudited financial results. The meeting, which was held through video conferencing, commenced at 4:30 p.m. and concluded at 5:25 p.m.

The company's statutory auditors, M/s. R K Jagetiya & Co., Chartered Accountants (Firm Registration No. 146264W), have issued an unmodified opinion in their Limited Review Report on the unaudited financial results. This indicates that the auditors did not find any material misstatements or issues that would require modifications to the financial statements.

Regulatory Compliance and Trading Window

In compliance with SEBI regulations, Amkay Products has declared that the trading window for dealing in the company's securities will reopen 48 hours after the public announcement of the results. This measure is in line with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, aimed at preventing insider trading and ensuring fair market practices.

Investors and stakeholders should note that while the company has experienced revenue growth, the widening losses and increased expenses may require closer scrutiny of Amkay Products' operational efficiency and cost management strategies in the coming quarters.